8 completed, 2 not yet recruiting, 1 active not recruiting, 1 recruiting. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 8, Not yet recruiting 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow fezolinetant: new trials by email Literature Review of fezolinetant trials Research Report on fezolinetant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause Fezolinetant - Hot Flashes | Phase 3 | Not yet recruiting | Astellas Pharma Inc | 100 | 2026-10-31 | 2026-09-28 |
| Fezolinetant and Vascular Health and Brain Health Placebo, Fezolinetant - Menopause Hot Flashes | Phase 3 | Not yet recruiting | Rebecca Thurston | 220 | 2026-09-25 | 2026-08-19 |
| Focusing on the Menopausal Transition to Improve Mid-Life Women's Health Metformin, semaglutide, Anti-hypertensives - Menopause, Menopause Hot Flashes | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 200 | 2026-03-01 | 2026-07-21 |
| A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy Fezolinetant, Placebo, Tamoxifen - Hot Flashes | Phase 3 | Active not recruiting | Astellas Pharma Global Development, Inc. | 982 | 2024-07-31 | 2026-10-27 |
| A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause Fezolinetant, Placebo - Hot Flashes | Phase 3 | Completed | Astellas Pharma Inc | 277 | 2024-02-22 | 2026-04-08 |
| A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause Fezolinetant, Placebo - Hot Flashes | Phase 3 | Completed | Astellas Pharma Inc | 410 | 2024-02-16 | 2025-12-23 |
| A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause fezolinetant, placebo - Vasomotor Symptoms | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 453 | 2021-11-08 | 2024-10-26 |
| A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause Fezolinetant - Hot Flashes | Phase 3 | Completed | Astellas Pharma China, Inc. | 150 | 2020-07-30 | 2025-01-31 |
| A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause Fezolinetant, Placebo - Hot Flashes | Phase 3 | Completed | Astellas Pharma China, Inc. | 302 | 2020-03-17 | 2025-01-31 |
| A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause fezolinetant, placebo - Hot Flashes | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 527 | 2019-07-11 | 2024-11-04 |
| A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause fezolinetant, placebo - Hot Flashes | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 1831 | 2019-07-10 | 2024-11-05 |
| A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 Fezolinetant, placebo - Hot Flashes | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 501 | 2019-07-10 | 2024-11-05 |
Hot Flashes (10)
Astellas Pharma Global Development, Inc. (5) · Astellas Pharma Inc (3) · Astellas Pharma China, Inc. (2) · Rebecca Thurston (1) · University of Colorado, Denver (1)
Canada (5) · Czechia (5) · Poland (5) · Spain (5) · United Kingdom (5) · United States (5) · Hungary (3) · China (2) · Denmark (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Latvia (2) · Netherlands (2)
Nanette Santoro, MD (1) · Rebecca C Thurston, PhD (1)
PMID 39739195, PMID 37990323, PMID 38396203, PMID 38775925, PMID 40044127, PMID 41259888, PMID 36897180, PMID 36924778, PMID 37870510, PMID 38818887, PMID 38818888, PMID 39557487, PMID 40773756
2018 (2), 2019 (1)